文献速递血脂与心血管预防高血压心力衰竭与心肌病

预测风险与预期获益指导CKM综合征心血管病一级预防决策

Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
PubMed 文献 · Circulation · 2026-06-09

该科学声明由AHA与ACC联合发布,阐述在心血管-肾脏-代谢综合征的一级预防中,使用PREVENT系列方程(PREVENT-CVD、PREVENT-ASCVD、PREVENT-HF)评估特定结局风险,并结合治疗相对风险降低估算预期获益(绝对风险降低),以指导预防性治疗启动与强化。声明详述了使用结局特异性PREVENT方程的理由、选定风险阈值的证据基础及潜在人群影响,并提供将风险评估作为共享决策第一步的实践指导。

要点

  • 2025高血压指南和2026血脂异常指南推荐PREVENT方程指导降压和降脂治疗启动与强化。
  • 2026 CKM综合征指南推荐使用PREVENT方程及结局特异性风险阈值进行分期和亚临床CVD检测。
  • 将预测风险与治疗预期相对风险降低结合,估算绝对风险降低以指导药物治疗决策。

核心结论

  • 在CKM综合征心血管病一级预防中,应整合PREVENT方程预测的结局特异性风险与治疗预期相对风险降低,估算绝对风险降低以指导治疗决策。

研究设计与样本

  • 美国心脏协会(AHA)与美国心脏病学会(ACC)联合发布的科学声明,阐述风险预测与预期获益指导决策的理论依据、证据基础及实践指导。

主要发现

  • 2025 AHA/ACC高血压指南和2026 AHA/ACC血脂异常指南均纳入定量风险评估,推荐PREVENT方程分别指导降压和降脂治疗的启动与强化。
  • 2026 AHA/ACC CKM综合征指南推荐使用PREVENT方程及结局特异性风险阈值进行分期、亚临床心血管病检测及CKM治疗决策。
  • 声明详述了使用结局特异性PREVENT方程(PREVENT-CVD、PREVENT-ASCVD、PREVENT-HF)的理由及选定风险阈值的证据基础。

关键数值与推荐

  • 推荐使用PREVENT-CVD、PREVENT-ASCVD和PREVENT-HF方程评估对应结局的预测风险。
  • 将预测风险与治疗预期相对风险降低结合,估算绝对风险降低(预期获益)以指导药物治疗决策。
  • 2026 CKM综合征指南提供结局特异性风险阈值用于分期、亚临床CVD检测及治疗启动与强化决策。

临床怎么用

  • 将风险评估作为共享决策的第一步,用于CKM综合征患者或高危人群的一级预防。
  • 利用PREVENT方程预测风险并结合治疗预期相对风险降低,评估绝对风险降低以指导预防性治疗启动与强化。
  • 关注并解决风险意识、风险沟通及循证预防治疗最佳实施方面的差距。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current clinical practice guidelines for the primary prevention of cardiovascular disease recommend risk assessment to align the type and intensity of preventive efforts with an individual's risk. The 2025 American Heart Association/American College of Cardiology guideline for the prevention, detection, evaluation, and management of high blood pressure in adults and the 2026 American Heart Association/American College of Cardiology guideline on the management of dyslipidemia incorporate quantitative risk assessment, recommending the PREVENT (Predicting Risk of Cardiovascular Disease Events) equations to guide initiation and intensification of antihypertensive and lipid-lowering therapies, respectively. Given the growing awareness of the clustering of cardiovascular-kidney-metabolic risk factors along with the expanding armamentarium of cardioprotective therapies for obesity, diabetes, and chronic kidney disease, a harmonized approach that comprehensively assesses and addresses risk across these interconnected conditions is needed. The 2026 American Heart Association/American College of Cardiology guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome provides recommendations for the use of the PREVENT equations with outcome-specific risk thresholds for staging, detection of subclinical cardiovascular disease, and decision-making regarding initiation and intensification of cardiovascular-kidney-metabolic therapies. This approach integrates predicted risk (using PREVENT-CVD [cardiovascular disease], PREVENT-ASCVD [atherosclerotic cardiovascular disease], and PREVENT-HF [heart failure]) with the relative risk reduction expected from treatment for each outcome to estimate the expected benefit (ie, absolute risk reduction) from drug therapy. This scientific statement details the rationale for using outcome-specific PREVENT equations, the evidence base for selected risk thresholds, and the potential population-level impact of these recommendations. This scientific statement also offers practical guidance for applying risk assessment as the first step in shared decision-making and for addressing gaps in awareness, risk communication, and optimal implementation of evidence-based preventive therapies to improve outcomes in individuals with or at risk for cardiovascular-kidney-metabolic syndrome.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Khan SS, Bhave N, Blumenthal RS, et al. Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2026. PMID: 42263147. doi:10.1161/CIR.0000000000001447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。